Jerome Charles Bressi - 14 Aug 2024 Form 3 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Exhibit 24 - Power of Attorney; Chief Regulatory and Quality Officer
Signature
/s/ Cindy R. Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
14 Aug 2024
Net transactions value
$0
Form type
3
Filing time
21 Aug 2024, 16:26:21 UTC
Next filing
13 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FATE Common Stock 276,183 14 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FATE Stock Option (Right to Buy) 14 Aug 2024 Common Stock 50,000 $13.53 Direct F1
holding FATE Stock Option (Right to Buy) 14 Aug 2024 Common Stock 17,007 $21.94 Direct F1
holding FATE Stock Option (Right to Buy) 14 Aug 2024 Common Stock 42,446 $39.87 Direct F2
holding FATE Stock Option (Right to Buy) 14 Aug 2024 Common Stock 425,000 $6.77 Direct F3
holding FATE Stock Option (Right to Buy) 14 Aug 2024 Common Stock 425,000 $6.76 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 The option vests in 48 equal monthly installments following January 1, 2022 such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such date.
F3 The option vests in 36 equal monthly installments following January 1, 2023 such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such date.
F4 The option vests in 36 equal monthly installments following January 1, 2024 such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.

Remarks:

Exhibit 24 - Power of Attorney; Chief Regulatory and Quality Officer